Thermo Fisher Scientific Inc. (TMO) Financial Statements
Thermo Fisher Scientific Inc. (TMO) reported trailing twelve-month revenue of $46.3B (up 7.2% year on year) and net income of $7.0B as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $7.3B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 249.1B
- P/E TTM
- 36.2
- Dividend yield
- 0.3%
- 52-week
- —
- Next earnings
- 27 Jan, in 95 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26. Results for the next quarter were released 21 Oct; these figures move once the 10-Q is filed.
| Line | FY2009 Dec 09 | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.91 | 10.39 | 11.56 | 12.51 | 13.09 | 16.89 | 16.97 | 18.27 | 20.92 | 24.36 | 25.54 | 32.22 | 39.21 | 44.92 | 42.86 | 42.88 | 44.56 | 46.34 | |
| Gross profit | 4.76 | 5.13 | 5.83 | 6.41 | 6.78 | 8.95 | 9.38 | 10.06 | 11.94 | — | — | — | 19.64 | 18.97 | 17.10 | 17.70 | 18.24 | 18.91 | |
| Research & development | — | — | — | 0.38 | 0.40 | 0.69 | 0.69 | 0.75 | 0.89 | 0.97 | 1.00 | 1.18 | 1.41 | 1.47 | 1.34 | 1.39 | 1.40 | 1.40 | |
| Operating income | 1.00 | 1.19 | 1.25 | 1.48 | 1.61 | 2.50 | 2.34 | 2.46 | 2.96 | 3.78 | 4.59 | 7.79 | 10.03 | 8.39 | 6.86 | 7.34 | 7.75 | 8.15 | |
| Pre-tax income | 0.88 | 1.09 | 1.13 | 1.27 | 1.32 | 2.09 | 1.94 | 2.02 | 2.43 | 3.26 | 4.07 | 7.23 | 8.84 | 7.84 | 6.30 | 7.04 | 7.31 | 7.64 | |
| Income tax | 0.06 | 0.10 | 0.11 | 0.01 | 0.04 | 0.19 | -0.04 | -0.00 | 0.20 | 0.32 | 0.37 | 0.85 | 1.11 | 0.70 | 0.28 | 0.66 | 0.55 | 0.60 | |
| Net income | 0.85 | 1.04 | 1.33 | 1.18 | 1.27 | 1.89 | 1.98 | 2.02 | 2.23 | 2.94 | 3.70 | 6.38 | 7.73 | 6.96 | 6.00 | 6.34 | 6.70 | 6.97 | |
| Diluted EPS ($) | 2.01 | 2.53 | 3.46 | 3.21 | 3.48 | 4.71 | 4.92 | 5.09 | 5.59 | 7.24 | 9.17 | 15.96 | 19.46 | 17.63 | 15.45 | 16.53 | 17.74 | 18.59 | |
| Diluted shares (bn) | 0.423 | 0.409 | 0.385 | 0.367 | 0.366 | 0.402 | 0.402 | 0.397 | 0.398 | 0.406 | 0.403 | 0.399 | 0.397 | 0.394 | 0.388 | 0.383 | 0.378 | — |
USD billions · SEC XBRL
Thermo Fisher Scientific Inc. — questions
- What is Thermo Fisher Scientific Inc.'s revenue?
- $46.3B over the twelve months to 2026-06-30, up 7.2% year on year, from its 10-Q and 10-K filings.
- What is Thermo Fisher Scientific Inc.'s net income?
- $7.0B over the twelve months to 2026-06-30.
- What is Thermo Fisher Scientific Inc.'s free cash flow?
- $7.3B over the twelve months to 2026-06-30.
- What are Thermo Fisher Scientific Inc.'s diluted earnings per share?
- $18.59 over the twelve months to 2026-06-30.
Every figure on this page comes from Thermo Fisher Scientific Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.